blood cancers

Oncology

Expanding the haematology toolkit: Insights and operational ...

With over 8,200 abstracts accepted, ASH 2025 showcased breakthroughs in sickle cell disease, platelet disorders, and next-generation cell therapies.

Oncology

Targeting blood cancers with high unmet need

When it comes to myeloid malignancies such as acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS), treatment progress has been slow.

Oncology

ASCO 2025 interview with Dr Jason Westin

Breaking barriers to CAR T-cell therapy: The vision for expa...

Live from ASCO 2025: Prof. Dr Jason Westin discusses CAR-T Vision, patient access, and the push to expand therapy reach in rare blood cancers.

Oncology

ASCO 2024: Emphasising the art and science behind enhanced c...

The term “practice-changing” is often used when scientific advances promise to shift traditional treatment paradigms.

Oncology

Warning signs for CAR-T after secondary cancer cases

CAR-T treatments emerged as a major success for the pharma industry when first approved in 2017, but this has been muddied by concerns over secondary malignancies.

News

Catamaran joins the CAR-NK fleet, raising $42m in first roun...

Catamaran Bio has weighed anchor with a $42 million first-round financing that will be used to pull its off-the-shelf natural killer (NK) cell therapies for cancer through early-stage devel

Expanding the haematology toolkit: Insights and operational ...

Targeting blood cancers with high unmet need

Breaking barriers to CAR T-cell therapy: The vision for expa...

ASCO 2024: Emphasising the art and science behind enhanced c...

Warning signs for CAR-T after secondary cancer cases

Catamaran joins the CAR-NK fleet, raising $42m in first roun...

Allogeneic cell therapy isn’t dead, with Brian Culley

How to meet your physicians where they are online

blood cancers

Editor's Picks